Compare Expensify Inc (EXFY) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs New York Times Co — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: New York Times Co is far larger — about 51.4× Expensify Inc's market cap, and New York Times Co pays a 1.38% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and New York Times Co for 81 Days on average.
| EXFY | NYT | |
|---|---|---|
Market Cap | $208.82M | $10.74B |
Volume | 456,102 | 2,096,352 |
Sector | Technology | Media |
52-Week High | $2.72 | $85.86 |
52-Week Low | $0.75 | $54.66 |
Typical Hold Time | 41 Days | 81 Days |
Enterprise Value | $148.44M | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.30, up 1.32% today, showing technical bullish momentum with positive moving average signals. The company reported mixed Q2 2026 results with revenue of $33.9M and improved profitability, beating EPS estimates. Recent developments include AI-native ERP integrations and European card expansion, though fundamentals show negative net margins and high P/E ratio of 258.82. Analyst consensus is bullish with a $13.75 price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with strong analyst optimism contrasting with fundamental challenges. The stock's substantial discount to consensus target offers potential upside, but investors must weigh improving cash flow trends against persistent negative profitability and competitive pressures in the expense management sector.
The New York Times Company (NYT) trades at $66.60, up 2.62% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. Technical indicators show a bullish overall signal despite mixed moving averages, with key resistance at $67-68. The company maintains robust profitability with 13.19% net income margin and recently declared a $0.23 quarterly dividend payable October 22, 2026.
NYT presents a favorable investment case with 35% analyst buy ratings and $84 consensus price target suggesting 26% upside potential. Key opportunities include sustained digital subscription growth and AI-related legal developments, while risks involve the ongoing shareholder lawsuit alleging reporting bias and competitive pressures in digital media. The stock's current valuation at 27.75 P/E appears justified by its earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
